TG Therapeutics' Briumvi has shown strong revenue growth, with $310 million in FY24, and is expected to reach $540 million in ...

The ENHANCE Phase 3b clinical trial is evaluating the safety and efficacy of a modified treatment regimen of Briumvi for ...

Data from an open-label extension of VISIONARY-MS support an association between gold nanocrystals and neuronal repair and remyelination in patients with stable multiple sclerosis and visual deficits, ...

So, naturally the current outlook still calls for minimal exposure to the stock market at 0% to 20%. This red flag for active investors has remained in place since March 26, when ...

Amidst ongoing market volatility and heightened tensions between the U.S. and China, particularly impacting tech stocks with recent export restrictions on semiconductor companies, investors are keenly ...

The United States market has shown robust performance recently, rising 8.4% in the last week with all sectors gaining ground, and achieving a 5.9% increase over the past year, while earnings are ...